(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2017 (11.05.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/079673 A1

(51) **International Patent Classification**:
C12N 15/85 (2006.01) *C12N 5/074* (2010.01)

(21) **International Application Number**:
PCT/US2016/060699

(22) **International Filing Date**:
4 November 2016 (04.11.2016)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

62/251,032	4 November 2015 (04.11.2015)	US
62/337,258	16 May 2016 (16.05.2016)	US
62/366,503	25 July 2016 (25.07.2016)	US

(71) **Applicant**: **FATE THERAPEUTICS, INC.** [US/US]; 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US).

(72) **Inventors**: **VALAMEHR, Bahram**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **ABUJAROUR, Ramzey**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **LEE, Tom Tong**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **LAN, Weijie**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **CLARKE, Raedun**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **BJORDAHL, Ryan**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US).

(74) **Agents**: **GARELICK, Michael G.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2017/079673 A1

(54) **Title**: GENOMIC ENGINEERING OF PLURIPOTENT CELLS

(57) **Abstract**: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.